You are here: Industry Insights > biosimilar

News List

Terrosa® osteoporosis biosimilar treatment launched in Europe europeanpharmaceuticalreview
August 23, 2019
A new biosimilar drug to treat osteoporosis is now available across Europe after the patent for its reference product expired.
Dr Reddy’s launches Roche’s Avastin biosimilar in India expresspharma
August 21, 2019
Drug firm Dr Reddy’s Laboratories said it has launched a biosimilar of Roche’s Avastin in India indicated for the treatment of various types of cancers. The company’s biosimilar, Versavo, is available in ...
Richter Launches Biosimilar Teriparatide americanpharmaceuticalreview
August 21, 2019
Gedeon Richter has launched its biosimilar teriparatide, Terrosa® in Europe. The product is approved in adults for the same indications as Eli Lilly’s Forsteo®, i.e. used for the treatment of osteoporosis in postmenopausal women and ...
FDA approves Samsung Bioepis’ Humira biosimilar pharmaceutical-technology
July 26, 2019
South Korea-based Samsung Bioepis has received approval from the US Food and Drug Administration (FDA) for Hadlima, a biosimilar to Abbvie’s Humira (adalimumab) treatment.
RUXIENCE™ biosimilar granted approval from FDA europeanpharmaceuticalreview
July 26, 2019
The FDA has approved RUXIENCE (rituximab-pvvr), a biosimilar to Rituxan® (rituximab), for treatment of non-Hogkin’s lymphoma and other conditions.
FDA Approves Hadlima (adalimumab-bwwd), a Biosimilar to Humira drugs
July 25, 2019
Samsung Bioepis Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Hadlima (adalimumab-bwwd)...
First patient enrolled on clinical study for denosumab biosimilar europeanpharmaceuticalreview
July 24, 2019
An integrated Phase I/III trial has enrolled its first patient to test a biosimilar for denosumab to treat postmenopausal osteoporosis.
Prestige BioPharma Reports Positive Top-Line Phase III Results for Tuznue® (Trastuzumab Biosimilar) b3cnewswire
June 24, 2019
Prestige BioPharma announced positive top-line results from a Phase III global clinical trial (Troika) evaluating the efficacy, safety, and pharmacokinetics (PK) of biosimilar candidate HD201 to Herceptin (trastuzumab).
FDA approves Amgen and Allergan's KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab) worldpharmanews
June 20, 2019
FDA approves Amgen and Allergan's KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab).
Lannett Initiates Human Clinical Trial of Biosimilar Insulin Glargine americanpharmaceuticalreview
June 06, 2019
Lannett announced the commencement of a human clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page